Learning Objectives: -Recognize the symptomatology and molecular features of MDS that can inform accurate diagnosis, classification, prognosis, and personalized treatment planning -Cite updated guidelines and clinical evidence supporting the use of innovative therapies for the risk-adapted treatment of MDS -Implement team strategies to integrate modern and emerging therapeutics into the management of LR and HR MDS, including as first-line therapy, in ESA-refractory settings, and in the presence of high-risk features or disease-defining mutations -Address practical considerations of MDS care, including the use of modern tools for prognostic assessment, personalized treatment planning, appropriate dosing, AE management, and counseling on clinical trial enrollment
- Provider:Medical Learning Institute, Inc.
- Activity Link: https://PeerView.com/SZU
- Start Date: 2024-09-06 05:00:00
- End Date: 2024-09-06 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABIM - 1.0 Point; Credit Type(s): Patient Safety (ABIM) - Commercial Support: Source: Bristol Myers Squibb - Amount: 35949.0 - Is Kind Support: False Source: Geron - Amount: 12631.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Hematology, Internal Medicine, Medical Oncology